What is Nimrata Hunt’s IDEXX (IDXX) share ownership after these transactions?

Following the reported grants, vesting, and tax withholdings, Hunt directly owned 22,591.944 shares of IDEXX common stock. She also indirectly held 160 additional shares jointly with her spouse, reflecting combined family ownership disclosed in the Form 4.

IDEXX EVP Hunt reports stock grants and vesting

IDEXX Laboratories Executive Vice President Nimrata Hunt reported multiple equity awards, vesting events, and related share withholdings.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

IDEXX Laboratories Executive Vice President Nimrata Hunt reported multiple equity awards, vesting events, and related share withholdings. On February 12, 2026, Hunt received grants of 4,625 non-qualified stock options, 162 incentive stock options, and restricted stock units covering 1,094 and 1,620 shares of common stock.

On February 14, 2026, several restricted stock unit awards were exercised or converted, delivering a total of 2,587 shares of common stock, while 1,154 shares were withheld at $629.35 per share to satisfy tax obligations. After these transactions, Hunt directly owned 22,591.944 shares and indirectly held 160 shares jointly with a spouse.

Insider Trade Summary

2,587 shares exercised/converted

Exercise 16 txns

Insider Hunt Nimrata

Role Executive Vice President

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	204	$0.00	$0.00
Exercise	Restricted Stock Unit	207	$0.00	$0.00
Exercise	Restricted Stock Unit	301	$0.00	$0.00
Exercise	Restricted Stock Unit	367	$0.00	$0.00
Exercise	Restricted Stock Unit	1,508	$0.00	$0.00
Exercise	Common Stock	204	$0.00	$0.00
Exercise	Common Stock	207	$0.00	$0.00
Exercise	Common Stock	301	$0.00	$0.00
Exercise	Common Stock	1,508	$0.00	$0.00
Exercise	Common Stock	367	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,154	$629.35	$726K
Grant/Award	Non-Qualified Stock Option (right-to-buy)	4,625	$0.00	$0.00
Grant/Award	Incentive Stock Option (right-to-buy)	162	$0.00	$0.00
Grant/Award	Restricted Stock Unit	1,094	$0.00	$0.00
Grant/Award	Restricted Stock Unit	1,620	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (right-to-buy) — 4,625 contracts (Direct); Incentive Stock Option (right-to-buy) — 162 contracts (Direct); Restricted Stock Unit — 4,624 contracts (Direct); Common Stock — 22,591.944 shares (Direct); Common Stock — 160 shares (Indirect, jointly with spouse)

Footnotes (11)

F1. 1. Includes 10 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on December 31, 2025. There are a total of 401.944 shares held in the ESPP which has been increased by 0.005 shares due to a rounding calculation of previously issued fractional shares.
F2. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
F3. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
F4. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
F5. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.
F6. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027.
F7. Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.
F8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
F9. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
F10. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.
F11. Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did IDEXX (IDXX) EVP Nimrata Hunt report?

Executive Vice President Nimrata Hunt reported option and restricted stock unit grants, RSU vesting into common shares, and share withholdings for taxes. These transactions increased her direct and indirect ownership in IDEXX Laboratories common stock while settling tax liabilities in shares.

How many IDEXX (IDXX) stock options were granted to Nimrata Hunt?

Hunt received grants of 4,625 non-qualified stock options and 162 incentive stock options. According to footnotes, these options become exercisable in installments beginning February 14, 2027 and on February 14, 2030, aligning vesting with multi-year executive compensation schedules.

What restricted stock unit awards did Nimrata Hunt receive from IDEXX (IDXX)?

Hunt was granted restricted stock units covering 1,094 shares and 1,620 shares of IDEXX common stock. Footnotes state each RSU converts into one share and vests over three or four annual installments starting February 14, 2027, linking equity rewards to continued service.

How many IDEXX (IDXX) shares did Nimrata Hunt receive from RSU vesting?

On February 14, 2026, several restricted stock unit awards were exercised or converted into 2,587 shares of IDEXX common stock. These vesting events reflect previously granted RSUs reaching their scheduled vesting dates under the company’s long-term incentive plans.

Why were 1,154 IDEXX (IDXX) shares disposed of in Nimrata Hunt’s Form 4?

The filing shows 1,154 shares treated as a disposition at $629.35 per share to satisfy tax obligations by delivering shares. A footnote states this price was the IDEXX closing price on February 13, 2026, indicating a tax-withholding mechanism rather than an open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/17/2026 - 07:30 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Nimrata

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

04092

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/14/2026		M		204	A	$0	21,362.944⁽¹⁾	D
Common Stock	02/14/2026		M		207	A	$0	21,569.944	D
Common Stock	02/14/2026		M		301	A	$0	21,870.944	D
Common Stock	02/14/2026		M		1,508	A	$0	23,378.944	D
Common Stock	02/14/2026		M		367	A	$0	23,745.944	D
Common Stock	02/14/2026		F		1,154	D	$629.35⁽²⁾	22,591.944	D
Common Stock								160	I	jointly with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right-to-buy)	$617.2	02/12/2026		A		4,625		⁽³⁾	02/11/2036	Common Stock	4,625	$0	4,625	D
Incentive Stock Option (right-to-buy)	$617.2	02/12/2026		A		162		⁽⁴⁾	02/11/2036	Common Stock	162	$0	162	D
Restricted Stock Unit	⁽⁵⁾	02/12/2026		A		1,094		⁽⁵⁾	⁽⁵⁾	Common Stock	1,094	$0	1,094	D
Restricted Stock Unit	⁽⁶⁾	02/12/2026		A		1,620		⁽⁶⁾	⁽⁶⁾	Common Stock	1,620	$0	1,620	D
Restricted Stock Unit	⁽⁷⁾	02/14/2026		M			204	⁽⁷⁾	⁽⁷⁾	Common Stock	204	$0	0	D
Restricted Stock Unit	⁽⁸⁾	02/14/2026		M			207	⁽⁸⁾	⁽⁸⁾	Common Stock	207	$0	207	D
Restricted Stock Unit	⁽⁹⁾	02/14/2026		M			301	⁽⁹⁾	⁽⁹⁾	Common Stock	301	$0	602	D
Restricted Stock Unit	⁽¹⁰⁾	02/14/2026		M			367	⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	367	$0	1,101	D
Restricted Stock Unit	⁽¹¹⁾	02/14/2026		M			1,508	⁽¹¹⁾	⁽¹¹⁾	Common Stock	1,508	$0	0	D

Explanation of Responses:

1. 1. Includes 10 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on December 31, 2025. There are a total of 401.944 shares held in the ESPP which has been increased by 0.005 shares due to a rounding calculation of previously issued fractional shares.

2. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.

3. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.

4. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.

5. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.

6. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027.

7. Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.

8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.

9. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.

10. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.

11. Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR